SEELOS THERAPEUTICS INC (SEEL) Stock Price & Overview

NASDAQ:SEEL • US81577F3073

Current stock price

1.28 USD
-1.17 (-47.76%)
At close:
1.45 USD
+0.17 (+13.28%)
After Hours:

The current stock price of SEEL is 1.28 USD. Today SEEL is down by -47.76%. In the past month the price decreased by -64.44%. In the past year, price decreased by -99.83%.

SEEL Key Statistics

52-Week Range1.15 - 848.64
Current SEEL stock price positioned within its 52-week range.
1-Month Range1.15 - 8.8576
Current SEEL stock price positioned within its 1-month range.
Market Cap
563.2K
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-45.32
Dividend Yield
N/A

SEEL Stock Performance

Today
-47.76%
1 Week
-60.00%
1 Month
-64.44%
3 Months
-85.35%
Longer-term
6 Months -97.01%
1 Year -99.83%
2 Years -99.96%
3 Years -99.98%
5 Years -99.96%
10 Years N/A

SEEL Stock Chart

SEELOS THERAPEUTICS INC / SEEL Daily stock chart

SEEL Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to SEEL. When comparing the yearly performance of all stocks, SEEL is a bad performer in the overall market: 99.8% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SEEL Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SEEL. SEEL has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SEEL Earnings

Next Earnings DateNov 12, 2024
Last Earnings DateAug 2, 2024
PeriodQ2 / 2024
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise 22.88%

SEEL Forecast & Estimates

7 analysts have analysed SEEL and the average price target is 122.4 USD. This implies a price increase of 9462.5% is expected in the next year compared to the current price of 1.28.

For the next year, analysts expect an EPS growth of 97.05% and a revenue growth -81.25% for SEEL


Analysts
Analysts85.71
Price Target122.4 (9462.5%)
EPS Next Y97.05%
Revenue Next Year-81.25%

SEEL Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

SEEL Financial Highlights

Over the last trailing twelve months SEEL reported a non-GAAP Earnings per Share(EPS) of -45.32. The EPS decreased by -318.47% compared to the year before.


Income Statements
Revenue(TTM)2.01M
Net Income(TTM)4.09M
Industry RankSector Rank
PM (TTM) 203.13%
ROA 171.82%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%101.27%
Sales Q2Q%11.9%
EPS 1Y (TTM)-318.47%
Revenue 1Y (TTM)76.05%

SEEL Ownership

Ownership
Inst Owners21.58%
Shares440.00K
Float430.00K
Ins Owners73.41%
Short Float %N/A
Short RatioN/A

About SEEL

Company Profile

SEEL logo image Seelos Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York and currently employs 10 full-time employees. Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The firm operates under one segment which develops pharmaceutical products. The firm's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The firm's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.

Company Info

IPO: 1993-10-27

SEELOS THERAPEUTICS INC

300 Park Avenue, 2nd Floor

New York City NEW YORK 10022 US

CEO: Raj Mehra

Employees: 8

SEEL Company Website

Phone: 16462932100

SEELOS THERAPEUTICS INC / SEEL FAQ

What does SEELOS THERAPEUTICS INC do?

Seelos Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York and currently employs 10 full-time employees. Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The firm operates under one segment which develops pharmaceutical products. The firm's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The firm's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.


Can you provide the latest stock price for SEELOS THERAPEUTICS INC?

The current stock price of SEEL is 1.28 USD. The price decreased by -47.76% in the last trading session.


Does SEELOS THERAPEUTICS INC pay dividends?

SEEL does not pay a dividend.


How is the ChartMill rating for SEELOS THERAPEUTICS INC?

SEEL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


On which exchange is SEEL stock listed?

SEEL stock is listed on the Nasdaq exchange.


What is the market capitalization of SEEL stock?

SEELOS THERAPEUTICS INC (SEEL) has a market capitalization of 563.20K USD. This makes SEEL a Nano Cap stock.


Who owns SEELOS THERAPEUTICS INC?

You can find the ownership structure of SEELOS THERAPEUTICS INC (SEEL) on the Ownership tab.